Nancy Devlin
Nancy’s principal areas of research expertise are the measurement and valuation of patient reported health outcomes; the cost-effectiveness thresholds used in making judgements about value for money in health care; the use of MCDA in health care decision making; priority setting in health care; and measuring the production, performance and efficiency of hospitals. She has over 30 years of experience as a researcher and as an advisor to health care organisations, both in the public and private sectors, in the UK and internationally.
Nancy is Professor of Health Economics and Director of the Centre for Health Policy in the Melbourne School of Population and Global Health. She previously spent 10 years working for OHE as Director of Research. She also holds honorary chairs at the School of Health and Related Research at the University of Sheffield; and in the Economics Department at City University, London.
She has published over 100 original peer-reviewed journal articles on a wide range of empirical and theoretical topics in health economics. She is a co-author of numerous books, including Economic Analysis in Health Care, a leading textbook on health economics now in its second edition.
Publications and Insights
- Insight: Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?
- Publication: Anchoring Latent Scale Values for the EQ-5D-Y at 0 = Dead
- Publication: Valuing EQ-5D-Y Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?
- Publication: Can We Really Compare and Aggregate PRO Data Between People and Settings? Implications for Multi-Country Clinical Trials and HTA
- Publication: Exploring Variations in the Opportunity Cost Cost-effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England
- Publication: Public Preferences for Health Gains and Cures: A Discrete Choice Experiment
- Publication: Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology
- Publication: A New Valuation Method: Directly Eliciting Personal Utility Functions
- Publication: Age and Utilities: Issues for HTA
- Publication: Comparing the UK EQ-5D-3L and the English EQ-5D-5L Value Sets
- Publication: What is the Normative Basis for Selecting the Measure of ‘Average’ Preferences for Use in Social Choices?
- Insight: 5 Things You Should Do with EQ-5D Data
- Publication: An Analysis of NICE Technology Appraisal Decisions ‘Recommended in Line with Clinical Practice’
- Publication: Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
- Publication: An Investigation of the Feasibility and Cultural Appropriateness of Stated Preference Methods to Generate EQ-5D-5L Values in the United Arab Emirates
- Publication: Do Respondents Completing Abstract, Hypothetical Priority-setting Exercises Agree With the Policy Implications of Their Choices?
- Publication: What Determines the Shape of an EQ-5D Index Distribution?
- Publication: Time Trends in NICE HTA Decisions
- Publication: The Evolution of HTA in Emerging Markets Health Care Systems: Analysis to Support a Policy Response
- Publication: A Comparison of Alternative Variants of the Lead and Lag Time TTO
- Publication: How Much Should We Spend on the NHS?
- Publication: Cost-Effectiveness Thresholds: Economic and ethical issues